UroGen Pharma Ltd. — Director's Dealing 2023

Sep 8, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2023-09-07

Reporting Person: Wildman Daniel George (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-09-07	Stock Option (right ot buy)	$16.85	A	10000	Acquired	2033-09-07	Ordinary Shares (10000)	Direct

Footnotes

F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year.